Category Archives: Treatment

Delving deeper into the mechanisms fundamental to HIV-associated immunopathology using single-cell sequencing techniques: A scoping review of current literature

2024

Human immunodeficiency virus (HIV) infection has evolved into an established global pandemic over the past four decades; however, despite massive research investment globally, the precise underlying mechanisms which are fundamental...

Virtual care pathways for people living with HIV: A mixed-methods systematic review

2024

BACKGROUND: The COVID-19 pandemic prompted an unprecedented surge in virtual services, necessitating a rapid shift to digital healthcare approaches. This review focuses on evaluating the evidence of virtual care (VC)...

Liver damage during treatment with reverse-transcriptase inhibitors in HIV patients

2024

The advent of highly active antiretroviral therapy (HAART) in 1996 has markedly enhanced the life expectancy of people living with HIV (PLWH), largely due to the effectiveness of reverse transcriptase...

Efficacy and tollerability of INI-based 2-drug regimen in virosuppressed persons living with HIV: A systematic review and meta-analysis

2024

BACKGROUND: The aim of this meta-analysis was to synthesize the available evidence from the literature on the efficacy and safety of integrase inhibitor-based two drug regimens compared to triple drug...

Treatment failure among Sub-Sahara African children living with HIV: A systematic review and meta-analysis

2024

BACKGROUND: Antiretroviral treatment failure is a global issue, particularly in developing countries such as Sub-Saharan Africa. Prior research findings were highly variable and inconsistent across areas. As a result, the...

Burden of metabolic syndrome in the global adult HIV-infected population: A systematic review and meta-analysis

2024

Background Metabolic syndrome (MetS) elevates the risk of heart disease and stroke. In recent decades, the escalating prevalence of MetS among people living with HIV/AIDS (PLWHA) has garnered global attention....

The viral load monitoring cascade in HIV treatment programmes in sub-Saharan Africa: A systematic review

2024

BACKGROUND: The United Nations’ 95-95-95 (95% of people with HIV being aware of their diagnosis, 95% of those aware of their diagnosis being on treatment and 95% achieving viral suppression)...

Exploring intervention frameworks to improve utilization of elimination of mother-to-child transmission services in Africa: A scoping review

2024

BACKGROUND: Over the past two decades, intervention strategies to improve the use of the elimination of mother-to-child transmission (EMTCT) services have been implemented for several reasons. The reasons include elimination...

Retention in care among people living with HIV in Nigeria: A systematic review and meta-analysis

2024

BACKGROUND: In 2021, Nigeria had an estimated 1.9 million people living with the human immunodeficiency virus (PLHIV) and 1.7 million (90%) on antiretroviral therapy (ART). Study Design: A systematic review...

Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis

2024

INTRODUCTION: Among many antiretroviral drugs, tenofovir alafenamide is used extensively in combination regimens of tenofovir/emtricitabine or tenofovir/emtricitabine/bictegravir. However, concerns have arisen about the potential of tenofovir alafenamide to exacerbate hyperlipidaemia....

Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: A systematic review and meta-analysis

2024

Background Despite significant reductions in mother-to-child HIV-1 transmission risks due to the advancements and scale-up of antiretroviral therapy (ART), the global burden of HIV-1 drug resistance (HIVDR) in treatment-naive and...

Population pharmacokinetic simulations for dose optimization of tenofovir disoproxil fumarate in HIV-infected patients with moderate-to-severe renal impairment

2024

Tenofovir disoproxil fumarate (TDF) requires dosage adjustments from the standard 300 mg once daily to every 48–96 h for moderate-to-severe renal impairment to avoid excessive exposure. However, this extended interval...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!